文献速递妇科

奥拉帕利维持治疗在铂敏感复发性卵巢癌患者中的疗效:ORZORA试验中体细胞与胚系BRCA及其他同源重组修复基因突变状态的结果

Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
PubMed 文献 · Gynecol Oncol · 2023-04-06

ORZORA是一项开放标签、单臂、多中心试验,评估奥拉帕利维持治疗在铂敏感复发性卵巢癌患者中的疗效与安全性。177例患者接受奥拉帕利胶囊400毫克每日两次治疗,BRCAm队列中位随访22.3个月,BRCAm、sBRCAm、gBRCAm和非BRCA HRRm队列的中位PFS分别为18.0、16.6、19.3和16.4个月。结论认为奥拉帕利在sBRCAm与任何BRCAm患者中临床活性相似,非BRCA HRRm患者中亦观察到活性。

要点

  • BRCAm队列中位PFS为18.0个月,sBRCAm队列为16.6个月,gBRCAm队列为19.3个月,非BRCA HRRm队列为16.4个月。
  • BRCAm患者中21.8%报告健康相关生活质量改善,68.7%报告无变化。
  • 安全性特征与预期一致,支持奥拉帕利用于所有BRCA突变(包括sBRCA突变)的铂敏感复发性卵巢癌患者。

核心结论

  • 奥拉帕利维持治疗在sBRCAm与任何BRCAm的铂敏感复发性卵巢癌患者中临床活性相似,非BRCA HRRm患者中亦观察到活性。
  • ORZORA进一步支持奥拉帕利维持治疗用于所有BRCA突变(包括sBRCA突变)的铂敏感复发性卵巢癌患者。

研究设计与样本

  • 开放标签、单臂、多中心ORZORA试验(NCT02476968)。
  • 纳入≥2线治疗后对最近一次铂类化疗有响应、肿瘤携带胚系或体细胞BRCA突变或非BRCA同源重组修复突变的铂敏感复发性卵巢癌患者。
  • 177例患者接受奥拉帕利胶囊400毫克每日两次维持治疗直至疾病进展。
  • 筛查时前瞻性中心检测确定肿瘤BRCAm状态,后续检测确定gBRCAm或sBRCAm状态,预设非BRCA HRRm患者分配至探索性队列。
  • 共同主要终点为研究者评估的BRCAm和sBRCAm队列无进展生存期(PFS;修改版实体瘤疗效评价标准v1.1),次要终点包括健康相关生活质量和耐受性。

主要发现

  • 主要数据截止(2020年4月17日)时,BRCAm队列PFS中位随访22.3个月。
  • BRCAm、sBRCAm、gBRCAm和非BRCA HRRm队列的中位PFS(95%CI)分别为18.0(14.3-22.1)、16.6(12.4-22.2)、19.3(14.3-27.6)和16.4(10.9-19.3)个月。
  • BRCAm患者中21.8%报告健康相关生活质量改善,68.7%报告无变化。
  • 安全性特征与预期一致。

临床怎么用

  • 作者结论认为ORZORA进一步支持奥拉帕利维持治疗用于所有BRCA突变(包括sBRCA突变)的铂敏感复发性卵巢癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after ≥2 lines of treatment. METHODS: Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. The co-primary endpoints were investigator-assessed progression-free survival (PFS; modified Response Evaluation Criteria in Solid Tumors v1.1) in BRCAm and sBRCAm cohorts. Secondary endpoints included health-related quality of life (HRQoL) and tolerability. RESULTS: 177 patients received olaparib. At the primary data cut-off (17 April 2020), the median follow-up for PFS in the BRCAm cohort was 22.3 months. The median PFS (95% CI) in BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts was 18.0 (14.3-22.1), 16.6 (12.4-22.2), 19.3 (14.3-27.6) and 16.4 (10.9-19.3) months, respectively. Most patients with BRCAm reported improvements (21.8%) or no change (68.7%) in HRQoL and the safety profile was as expected. CONCLUSIONS: Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Pignata S, Oza A, Hall G, et al. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. Gynecol Oncol. 2023. PMID: 37030280. doi:10.1016/j.ygyno.2023.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。